TY - JOUR
T1 - Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma
AU - Crispen, Paul L.
AU - Sheinin, Yuri
AU - Roth, Timothy J.
AU - Lohse, Christine M.
AU - Kuntz, Susan M.
AU - Frigola, Xavier
AU - Houston Thompson, R.
AU - Boorjian, Stephen A.
AU - Dong, Haidong
AU - Leibovich, Bradley C.
AU - Blute, Michael L.
AU - Kwon, Eugene D.
PY - 2008/8/15
Y1 - 2008/8/15
N2 - Purpose: Although the prognostic value of B7-H1 and B7-H4 expression by tumor cells in clear cell renal cell carcinoma (ccRCC) has been established, the role of B7-H3 is unknown. As such, we evaluated the association of B7-H3 expression with clinicopathologic outcomes in patients treated for ccRCC. Experimental Design: Nephrectomy specimens from 743 consecutive patients treated for ccRCC at our institution from 1990 to 1999 were evaluated for B7-H3 expression by immunohis-tochemical staining. Associations of B7-H 3 expression with clinical and pathologic features were evaluated using x2 and Fisher's exact tests. Associations of B7-H3 expression with death from RCC were evaluated using Cox proportional hazards regression models. Results: B7-H3 expression by tumor cells or tumor vasculature was noted in 17% and 95% of specimens, respectively. The presence of either tumor cell or diffuse tumor vasculature expression of B7-H3 was present in 46% of specimens and was associated with multiple adverse clinical and pathologic features. After multivariable adjustment, the presence of either tumor cell or diffuse tumor vasculature B7-H3 expression was significantly associated with an increased risk of death from RCC (risk ratio, 1.38; 95% confidence interval, 1.03-1.84; P = 0.029). Conclusions: Both tumor cell and tumor vasculature B7-H3 expression convey important information to predict ccRCC outcomes. Collectively, our past and present studies pertaining to B7-H ligand expression indicate that ccRCC may use redundant mechanisms to compromise host antitumoral immunity. Future studies will focus on the effect of combined B7-H ligand expression in RCC.
AB - Purpose: Although the prognostic value of B7-H1 and B7-H4 expression by tumor cells in clear cell renal cell carcinoma (ccRCC) has been established, the role of B7-H3 is unknown. As such, we evaluated the association of B7-H3 expression with clinicopathologic outcomes in patients treated for ccRCC. Experimental Design: Nephrectomy specimens from 743 consecutive patients treated for ccRCC at our institution from 1990 to 1999 were evaluated for B7-H3 expression by immunohis-tochemical staining. Associations of B7-H 3 expression with clinical and pathologic features were evaluated using x2 and Fisher's exact tests. Associations of B7-H3 expression with death from RCC were evaluated using Cox proportional hazards regression models. Results: B7-H3 expression by tumor cells or tumor vasculature was noted in 17% and 95% of specimens, respectively. The presence of either tumor cell or diffuse tumor vasculature expression of B7-H3 was present in 46% of specimens and was associated with multiple adverse clinical and pathologic features. After multivariable adjustment, the presence of either tumor cell or diffuse tumor vasculature B7-H3 expression was significantly associated with an increased risk of death from RCC (risk ratio, 1.38; 95% confidence interval, 1.03-1.84; P = 0.029). Conclusions: Both tumor cell and tumor vasculature B7-H3 expression convey important information to predict ccRCC outcomes. Collectively, our past and present studies pertaining to B7-H ligand expression indicate that ccRCC may use redundant mechanisms to compromise host antitumoral immunity. Future studies will focus on the effect of combined B7-H ligand expression in RCC.
UR - http://www.scopus.com/inward/record.url?scp=52649160243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52649160243&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-08-0536
DO - 10.1158/1078-0432.CCR-08-0536
M3 - Article
C2 - 18694993
AN - SCOPUS:52649160243
SN - 1078-0432
VL - 14
SP - 5150
EP - 5157
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 16
ER -